Last reviewed · How we verify
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
NA trial testing PREHAB in Pancreas Cancer in 16 participants. Participants enrolled and being followed up; not accepting new ones.
| Lead sponsor | Cedars-Sinai Medical Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 16 |
| Start date | 15 May 2023 |
| Primary completion | 15 October 2025 |
| Estimated completion | 1 April 2027 |
| Sites | 1 location across United States |
Cedars-Sinai Medical Center
18 and older, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
PREHAB Program feasibility will be measured by tracking participant attendance at PREHAB sessions. PREHAB will be considered feasible if 50% of participants attend at least 60% of scheduled sessions. PREHAB session feasibility is defined as at least 50% of participants attending at least 60% of scheduled sessions
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 10 |
PREHAB program safety will be evaluated by monitoring unanticipated problems involving risk to subjects or others (UPIRSO). PREHAB Program Safety will be assessed through the reporting of unanticipated problems from the baseline visit through to the 3 Month visit.
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 2 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 1 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 2 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 2 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 1 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 1 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 1 |
| Group | Value | 95% CI |
|---|---|---|
| Supervised Prehabilitation Exercise Program | 1 |
Time frame: PREHAB session 1 through to the 3 Month Follow-Up, an average of 5 months. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.
| Reaction | System | Supervised Prehabilitation… |
|---|---|---|
| Sepsis | Infections and infestations | — |
| Anemia | Blood and lymphatic system disorders | — |
| Fever | General disorders | — |
| Diarrhea | Gastrointestinal disorders | — |
| Confusion | Psychiatric disorders | — |
| Reaction | System | Supervised Prehabilitation… |
|---|---|---|
| Fatigue | General disorders | — |
| Nausea | Gastrointestinal disorders | — |
| Abdominal Pain | Gastrointestinal disorders | — |
| Alkaline Phosphatase Increased | Investigations | — |
| Alanine Aminotransferase Increased | Investigations | — |
| Anemia | Blood and lymphatic system disorders | — |
| Aspartate Aminotransferase Increased | Investigations | — |
| Back Pain | Musculoskeletal and connective tissue disorders | — |
| Blood Bilirubin Increased | Investigations | — |
| Constipation | Gastrointestinal disorders | — |
| Diarrhea | Gastrointestinal disorders | — |
| Dizziness | Nervous system disorders | — |
| Dyspnea | Respiratory, thoracic and mediastinal disorders | — |
| Headache | Nervous system disorders | — |
| Hyperglycemia | Metabolism and nutrition disorders | — |
| Hypocalcemia | Metabolism and nutrition disorders | — |
| Hypokalemia | Metabolism and nutrition disorders | — |
| Hyponatremia | Vascular disorders | — |
| Hypotension | Vascular disorders | — |
| Platelet Count Decreased | Investigations | — |
| Vertigo | Ear and labyrinth disorders | — |
Most-reported serious reactions: Sepsis, Anemia, Fever, Diarrhea, Confusion.
Data from ClinicalTrials.gov NCT05692323 adverse events section.
The purpose of this study is to assess the use of an exercise program in people with pancreatic cancer.
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
Trials testing the same drug.
Currently open trials in the same condition.
Trials by the same sponsor.
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05692323.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing